fasudil has been researched along with Atherosclerosis in 4 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Atherosclerosis: A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The current study was designed to investigate the potential beneficial therapeutic outcome of Rho kinase inhibitor (fasudil) against hypercholesterolemia-induced myocardial and vascular injury in rabbits together with diet modification." | 7.85 | Rho kinase inhibitor fasudil mitigates high-cholesterol diet-induced hypercholesterolemia and vascular damage. ( Abdali, NT; Ibrahim, TM; Said, E; Yaseen, AH, 2017) |
| "The current study was designed to investigate the potential beneficial therapeutic outcome of Rho kinase inhibitor (fasudil) against hypercholesterolemia-induced myocardial and vascular injury in rabbits together with diet modification." | 3.85 | Rho kinase inhibitor fasudil mitigates high-cholesterol diet-induced hypercholesterolemia and vascular damage. ( Abdali, NT; Ibrahim, TM; Said, E; Yaseen, AH, 2017) |
| "We evaluated the ratio of phospho myosin-binding subunit (p-MBS) on myosin light-chain phosphatase to total MBS in peripheral leukocytes by Western blot analysis and forearm blood flow (FBF) response to the ROCK inhibitor fasudil using strain-gauge plethysmography in 36 healthy subjects and 39 patients with cardiovascular diseases." | 3.77 | Measurement of Rho-associated kinase (ROCK) activity in humans: validity of leukocyte p-MBS/t-MBS in comparison with vascular response to fasudil. ( Chayama, K; Fujii, Y; Fujimura, N; Goto, C; Hata, T; Hidaka, T; Higashi, Y; Idei, N; Kihara, Y; Liao, JK; Maruhashi, T; Mikami, S; Noma, K; Soga, J, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdali, NT | 1 |
| Yaseen, AH | 1 |
| Said, E | 1 |
| Ibrahim, TM | 1 |
| Wu, DJ | 1 |
| Xu, JZ | 1 |
| Wu, YJ | 1 |
| Jean-Charles, L | 1 |
| Xiao, B | 1 |
| Gao, PJ | 1 |
| Zhu, DL | 1 |
| Hata, T | 1 |
| Goto, C | 2 |
| Soga, J | 1 |
| Hidaka, T | 1 |
| Fujii, Y | 1 |
| Idei, N | 1 |
| Fujimura, N | 1 |
| Maruhashi, T | 1 |
| Mikami, S | 1 |
| Kihara, Y | 1 |
| Chayama, K | 2 |
| Noma, K | 2 |
| Liao, JK | 2 |
| Higashi, Y | 2 |
| Nishioka, K | 1 |
| Jitsuiki, D | 1 |
| Umemura, T | 1 |
| Ueda, K | 1 |
| Kimura, M | 1 |
| Nakagawa, K | 1 |
| Oshima, T | 1 |
| Yoshizumi, M | 1 |
4 other studies available for fasudil and Atherosclerosis
| Article | Year |
|---|---|
Rho kinase inhibitor fasudil mitigates high-cholesterol diet-induced hypercholesterolemia and vascular damage.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Alanine Transaminase; Animals; Aorta; Aspartate Amino | 2017 |
Effects of fasudil on early atherosclerotic plaque formation and established lesion progression in apolipoprotein E-knockout mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Apolipoproteins E; Atherosclerosis; Blood Pr | 2009 |
Measurement of Rho-associated kinase (ROCK) activity in humans: validity of leukocyte p-MBS/t-MBS in comparison with vascular response to fasudil.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Atherosclerosis; Blood Flow Velocity; Ca | 2011 |
Roles of rho-associated kinase and oxidative stress in the pathogenesis of aortic stiffness.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acetylcholine; Adult; Aortic Diseases; Atherosclerosi | 2007 |